|NASDAQ: GMAB||Healthcare / Biotechnology / Denmark|
|37.76||+0.2000||+0.53%||Vol 337.01K||1Y Perf 3.81%|
|Mar 31st, 2023 16:00 DELAYED|
|- -||0.12 0.32%|
|Target Price||42.09||Analyst Rating||Hold 2.59|
|Potential %||11.47||Finscreener Ranking||— -|
|Insiders Trans % 3/6/12 mo.||-/-/-||Value Ranking||★★★★+ 57.76|
|Insiders Value % 3/6/12 mo.||-/-/-||Growth Ranking||★★★★★ 79.87|
|Insiders Shares Cnt. % 3/6/12 mo.||-/-/-||Income Ranking||— -|
|Price Range Ratio 52W %||54.29||Earnings Rating||—|
|Market Cap||24.64B||Earnings Date||10th May 2023|
Today's Price Range
5 Year PE Ratio Range
|Mngmt Effectiveness||Value||Industry||S&P 500||US Markets|
ROE (5Y Avg)
ROE last 12 Months
ROA (5Y Avg)
ROA last 12 Months
ROC (5Y Avg)
ROC last 12 Months
Return on invested Capital Q
Return on invested Capital Y
|Valuation||Value||Industry||S&P 500||US Markets|
|Financial Strength||Value||Industry||S&P 500||US Markets|
|Profitability||Value||Industry||S&P 500||US Markets|
|Revenue||Value||Industry||S&P 500||US Markets|
|Dividends||Value||Industry||S&P 500||US Markets|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||10th May 2023|
|Estimated EPS Next Report||0.13|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||418.39K|
|Avg. Monthly Volume||518.94K|
|Avg. Quarterly Volume||530.69K|
Genmab A/S (NASDAQ: GMAB) stock closed at 37.76 per share at the end of the most recent trading day (a 0.53% change compared to the prior day closing price) with a volume of 337.01K shares and market capitalization of 24.64B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 781 people. Genmab A/S CEO is Jan G. J. van de Winkel.
The one-year performance of Genmab A/S stock is 3.81%, while year-to-date (YTD) performance is -10.9%. GMAB stock has a five-year performance of %. Its 52-week range is between 26.19 and 47.5, which gives GMAB stock a 52-week price range ratio of 54.29%
Genmab A/S currently has a PE ratio of 36.30, a price-to-book (PB) ratio of 7.50, a price-to-sale (PS) ratio of 20.87, a price to cashflow ratio of 53.30, a PEG ratio of 2.32, a ROA of 20.68%, a ROC of 22.45% and a ROE of 23.59%. The company’s profit margin is 52.71%, its EBITDA margin is 61.40%, and its revenue ttm is $1.35 Billion , which makes it $2.05 revenue per share.
Of the last four earnings reports from Genmab A/S, there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $0.13 for the next earnings report. Genmab A/S’s next earnings report date is 10th May 2023.
The consensus rating of Wall Street analysts for Genmab A/S is Hold (2.59), with a target price of $42.09, which is +11.47% compared to the current price. The earnings rating for Genmab A/S stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Genmab A/S has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Genmab A/S has a Neutral technical analysis rating based on Technical Indicators (ADX : 22.77, ATR14 : 0.70, CCI20 : 114.83, Chaikin Money Flow : 0.00, MACD : -0.03, Money Flow Index : 73.40, ROC : 5.74, RSI : 55.61, STOCH (14,3) : 92.75, STOCH RSI : 0.91, UO : 58.50, Williams %R : -7.25), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Genmab A/S in the last 12-months were:
|Analyst Ratings||Current||1 M ago||3 M ago|
|Summary Rating||Moderate Buy||Moderate Buy||Hold|
Genmab is a Copenhagen-based cancer drug developer best known for its antibody technology platforms, DuoBody and HexaBody, and multiple myeloma drug Darzalex (daratumumab), which is partnered with Johnson & Johnson. The company is the creator of Tepezza for thyroid eye disease (partnered with Horizon) and Kesimpta for relapsing multiple sclerosis (partnered with Novartis) and has several pipeline candidates targeting other oncologic indications and autoimmune diseases.
CEO: Jan G. J. van de Winkel
Telephone: +45 70202728
Address: Kalvebod Brygge 43, Copenhagen V 1560, , DK
Number of employees: 781
Mon, 06 Feb 2023 12:30 GMT Analysts Offer Insights on Healthcare Companies: Regeneron (REGN), Genmab (GMAB) and Immunovant (IMVT)- TipRanks. All rights reserved.
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
General partner of Finscreener is SLOVAKODATA, a.s.
Looks like you are using AdBlock.
The revenue earned from advertising enables us to provide the quality content you are trying to reach on this website. In order to view this page, please disable AdBlock or purchase Premium.
Sign in if you already have Premium account.
This could take some time, please wait.